Comparative Pharmacology
Head-to-head clinical analysis: CHOLAC versus LAX LYTE WITH FLAVOR PACKS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLAC versus LAX LYTE WITH FLAVOR PACKS.
CHOLAC vs LAX-LYTE WITH FLAVOR PACKS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, which lower the colonic pH. This acidification traps ammonia (NH3) as ammonium (NH4+) in the gut lumen, reducing serum ammonia levels. Additionally, the osmotic effect of lactulose draws water into the colon, producing a laxative effect.
Osmotic laxative: polyethylene glycol (PEG) retains water in the intestinal lumen, increasing stool volume and stimulating peristalsis. Electrolytes (sodium, potassium, chloride, bicarbonate) prevent electrolyte depletion.
15-30 mL (10-20 g lactulose) orally once daily, titrated to produce 2-3 soft stools per day; maximum dose 60 mL/day. For hepatic encephalopathy: 30-45 mL (20-30 g) orally 3-4 times daily, titrated to 2-3 soft stools per day.
Oral: 1 to 2 packets (4 to 8 g of polyethylene glycol 3350) dissolved in 4 to 8 ounces of water once daily, as needed for constipation. Maximum: 2 packets per day.
None Documented
None Documented
0.5-1.5 hours for lactulose; active metabolites (e.g., acetic acid) have negligible systemic half-life due to rapid local metabolism.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment (up to 20 hours).
Primarily fecal (biliary excretion of unchanged drug and metabolites); minimal renal excretion (<5%).
Primarily renal (30-50% unchanged) and biliary/fecal (50-70% as inactive metabolites).
Category C
Category C
Laxative
Laxative